SCHEMBL4866483

SCHEMBL4866483

COc1ccc(OC)c(OCC(O)CN2CCN(CC(=O)Nc3ccc4c(c3)CCC4)CC2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
ADRB2 P07550 1/20 0.53
ADRB1 P08588 1/20 0.53
ADRA2A P08913 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
ADRA1A P35348 1/20 0.53
DRD3 P35462 1/20 0.53
HTR2B P41595 1/20 0.53
KCNH2 Q12809 1/20 0.53
SCN5A Q14524 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPT P10636 2/20 0.52
POLB P06746 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4861692 0.90 CYP3A4 (0.65) ALDH1A1CYP3A4CYP2D6TSHRNFKB1
SCHEMBL4858045 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2KDM4EMAPTPOLB
SCHEMBL4863995 0.81 LMNA (0.63) ALDH1A1CYP3A4CYP2D6TSHRNFKB1
SCHEMBL4859389 0.81 CYP3A4 (0.52) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL7282209 0.81 CYP3A4 (0.72) ALDH1A1CYP3A4CYP2D6TSHRNFKB1
SCHEMBL7279229 0.81 TSHR (0.72) ALDH1A1CYP3A4CYP2D6TSHRNFKB1
SCHEMBL4862632 0.80 MEN1 (0.53) CYP3A4CYP2D6TSHRNFKB1ADRB2
SCHEMBL7288559 0.79 CYP3A4 (0.72) ALDH1A1CYP3A4CYP2D6TSHRNFKB1
SCHEMBL7288833 0.78 ALDH1A1 (0.70) ALDH1A1TSHRSMN1; SMN2KDM4EPOLB
SCHEMBL4866581 0.78 CYP3A4 (0.60) ALDH1A1CYP3A4CYP2D6TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 245/4885CYP3A4 655/4885CYP2D6 246/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885CYP3A4 598/4885CYP2D6 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.